Company Gubra A/S

Equities

GUBRA

DK0062266474

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Holdings

Company contact information

Sector

Sales per Business

Sales per region

Sector Bio Therapeutic Drugs

Delayed Nasdaq Copenhagen Other stock markets 15:59:37 17/05/2024 BST			5-day change	1st Jan Change
302 ^DKK	+1.00%		-10.65%	+141.60%

04-17	Gubra Unveils UCN2 as Novel Anti-Obesity Drug Candidate for Healthy Weight Loss	CI
03-29	Certain Shares of Gubra A/S are subject to a Lock-Up Agreement Ending on 29-MAR-2024.	CI

Gubra A/S is a Denmark-based biotechnology company specialized in high-end pre-clinical contract research and peptide-based drug discovery within metabolic and fibrotic diseases. The Companyâs operations are anchored around its advanced technology platforms and utilization of automation, robotization and digitalization, including machine learning (ML) and artificial intelligence (AI). The Company's business activity are divided into two segments: The CRO Segment offers specialized profitable pre-clinical contract research services at attractive margins within metabolic and fibrotic disease areas such as diabetes, obesity, chronic kidney disease; and The Discovery and Partnership Segment is based on an internal target and drug discovery engine for identification and design of peptide-based drug partnering candidates within metabolic and fibrotic diseases.

Number of employees: 220

DKK in Million	2022	Weight	2023	Weight	Delta
Pre-Clinical Contract Research 82.2 %	131	65.5 %	169	82.2 %	+29.04%
Discovery and Partnership 17.8 %	69	34.5 %	36	17.8 %	-46.99%

DKK in Million	2022	Weight	2023	Weight	Delta
United States 42.0 %	67	33.6 %	86	42.0 %	+28.36%
Germany 21.5 %	77	38.6 %	44	21.5 %	-42.86%
Denmark 16.1 %	15	7.5 %	33	16.1 %	+120.00%
Europe 15.3 %	30	15.1 %	31	15.3 %	+3.80%
Other 3.9 %	4	2.2 %	8	3.9 %	+84.04%
North America 1.4 %	6	3.0 %	3	1.4 %	-53.10%

Managers	Title	Age	Since
Niels Vrang FOU	Founder	56	31/12/07
Henrik Blou CEO	Chief Executive Officer	45	31/05/16
Kristian Borbos DFI	Director of Finance/CFO	46	31/07/22
Helle Kirstein Erichsen COO	Chief Operating Officer	-	31/03/17
Kristoffer Rigbolt CTO	Chief Tech/Sci/R&D Officer	-	30/04/22
Mads Buhl Axelsen CTO	Chief Tech/Sci/R&D Officer	66	31/07/22
Trine Nygaard Hamann PRN	Corporate Officer/Principal	-	29/02/20

Members of the board	Title	Age	Since
Arndt Justus Georg Schottelius BRD	Director/Board Member	58	31/12/21
Alexander Thomas Martensen-Larsen BRD	Director/Board Member	48	31/12/21
Jacob Jelsing FOU	Founder	50	31/12/07
Henriette Draebye Rosenquist BRD	Director/Board Member	55	31/12/21

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	16,349,703	5,000,292 ( 30.58 %)	59,271 ( 0.3625 %)	30.58 %

Name	Equities	%	Valuation
Jacob Jelsing 31.72 %	5,186,030	31.72 %	226 M kr
Niels Vrang 31.72 %	5,186,030	31.72 %	226 M kr
Danske Bank A/S (Investment Management) 4.348 %	710,825	4.348 %	31 M kr
Henrik Blou 3.098 %	506,499	3.098 %	22 M kr
GUBRA A/S 0.3625 %	59,271	0.3625 %	3 M kr
Schroder Investment Management (Europe) SA (Finland) 0.3058 %	50,000	0.3058 %	2 M kr
Cicero Fonder AB 0.1223 %	20,000	0.1223 %	871 641 kr
Sydbank A/S (Investment Management) 0.0119 %	1,939	0.0119 %	84 506 kr

Name	Equities	%	Valuation
GUBRA A/S 0.36%	59,271	0.36%	2,583,151 $

Gubra A/S

Hørsholm Kongevej 11B

2970, Hørsholm

+45 31 52 26 50

http://www.gubra.dk

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
GUBRA A/S	+141.60%	717M
VERTEX PHARMACEUTICALS INCORPORATED	+9.42%	115B
REGENERON PHARMACEUTICALS, INC.	+11.84%	106B
ARGENX SE	-2.74%	21.96B
BIONTECH SE	-14.15%	21.87B
GENMAB A/S	-5.29%	19.21B
BEIGENE, LTD.	-4.16%	18.08B
WUXI APPTEC CO., LTD.	-38.29%	17.71B
NEUROCRINE BIOSCIENCES, INC.	+7.99%	14.32B
SAREPTA THERAPEUTICS, INC.	+36.24%	12.42B

Bio Therapeutic Drugs